Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Fried

Showing results (301-310 of 383) with videos related to

Pageof 39
Sort By:
Epidemiology (Cambridge, Mass.)|January 31, 2023
Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial EmulationAlexander Breskin, Catherine Wiener, Adaora A Adimora, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 31, 2008
Hepatitis C virus: a critical appraisal of approaches to therapyDavid R Nelson, Gary L Davis, Ira Jacobson, et al.
Hepatology Communications|June 19, 2026
Progression of MASH to cirrhosis, decompensation, and mortality, and the utility of NITs for detection and risk stratificationPhilip N Newsome, Claudio Sartini, Heather L Morris, et al.
Chemmedchem|March 31, 2007
From dioxin to drug lead--the development of 2,3,7,8-tetrachlorophenothiazineKristian W Fried, Christopher M Schneider, Karl-Werner Schramm, et al.
Journal of Hepatology|September 10, 2002
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)Samuel S Lee, E Jenny Heathcote, K Rajender Reddy, et al.
The American Journal of Gastroenterology|July 6, 2004
Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trialPaul J Pockros, Robert Carithers, Paul Desmond, et al.
The American Journal of Gastroenterology|November 30, 2000
A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotypeM W Fried, M Shiffman, R K Sterling, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 5, 2023
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world CohortArun J Sanyal, Breda Munoz, Kenneth Cusi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 11, 2004
Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis CD Theodore, M W Fried, D E Kleiner, et al.
Alcoholism, Clinical and Experimental Research|April 25, 2003
Hepatitis C and alcohol: fundamental and translational research directionsTimothy R Morgan, David Brenner, James Everhart, et al.
Pageof 39

Showing results (301-310 of 383) with videos related to

Sort By:
Pageof 39
Epidemiology (Cambridge, Mass.)|January 31, 2023
Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial EmulationAlexander Breskin, Catherine Wiener, Adaora A Adimora, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 31, 2008
Hepatitis C virus: a critical appraisal of approaches to therapyDavid R Nelson, Gary L Davis, Ira Jacobson, et al.
Hepatology Communications|June 19, 2026
Progression of MASH to cirrhosis, decompensation, and mortality, and the utility of NITs for detection and risk stratificationPhilip N Newsome, Claudio Sartini, Heather L Morris, et al.
Chemmedchem|March 31, 2007
From dioxin to drug lead--the development of 2,3,7,8-tetrachlorophenothiazineKristian W Fried, Christopher M Schneider, Karl-Werner Schramm, et al.
Journal of Hepatology|September 10, 2002
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)Samuel S Lee, E Jenny Heathcote, K Rajender Reddy, et al.
The American Journal of Gastroenterology|July 6, 2004
Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trialPaul J Pockros, Robert Carithers, Paul Desmond, et al.
The American Journal of Gastroenterology|November 30, 2000
A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotypeM W Fried, M Shiffman, R K Sterling, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 5, 2023
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world CohortArun J Sanyal, Breda Munoz, Kenneth Cusi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 11, 2004
Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis CD Theodore, M W Fried, D E Kleiner, et al.
Alcoholism, Clinical and Experimental Research|April 25, 2003
Hepatitis C and alcohol: fundamental and translational research directionsTimothy R Morgan, David Brenner, James Everhart, et al.
Pageof 39